{"id":"levodopa-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Confusion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa (L-DOPA) is a precursor to dopamine that crosses the blood-brain barrier, unlike dopamine itself. Once in the brain, it is converted to dopamine by the enzyme aromatic amino acid decarboxylase (AADC), restoring dopamine neurotransmission in the basal ganglia. The infusion formulation provides continuous delivery to maintain stable dopamine levels and reduce motor fluctuations in advanced Parkinson's disease.","oneSentence":"Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:59.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced Parkinson's disease with motor fluctuations"}]},"trialDetails":[{"nctId":"NCT06107426","phase":"","title":"Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-01-24","conditions":"Parkinson's Disease (PD)","enrollment":450},{"nctId":"NCT07267065","phase":"PHASE1","title":"AAV2-hAADC for Parkinson's Disease (PDCS-01)","status":"NOT_YET_RECRUITING","sponsor":"Krzysztof Bankiewicz","startDate":"2026-02-01","conditions":"Parkinson's Disease (PD), Early Onset Parkinson Disease","enrollment":9},{"nctId":"NCT04750226","phase":"PHASE3","title":"Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-18","conditions":"Parkinson's Disease (PD)","enrollment":118},{"nctId":"NCT04379050","phase":"PHASE3","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-06-08","conditions":"Parkinson's Disease (PD)","enrollment":130},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT02726386","phase":"PHASE2","title":"A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2016-05-04","conditions":"Parkinson's Disease","enrollment":214},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT04064294","phase":"","title":"Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-08-22","conditions":"Parkinson Disease, Dyskinesia, Drug-Induced","enrollment":93},{"nctId":"NCT06432309","phase":"NA","title":"Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2022-07-01","conditions":"Parkinson Disease, Effect of Drug","enrollment":22},{"nctId":"NCT03562494","phase":"PHASE1","title":"VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2018-10-17","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT03374917","phase":"PHASE1","title":"A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-04-18","conditions":"Parkinson's Disease (PD)","enrollment":20},{"nctId":"NCT02096601","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-08-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT02480803","phase":"PHASE4","title":"INfusion VErsus STimulation in Parkinson's Disease","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-12-19","conditions":"Parkinson's Disease","enrollment":51},{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT04912115","phase":"PHASE2","title":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","status":"SUSPENDED","sponsor":"PharmaTher Inc.","startDate":"2021-10-05","conditions":"Dyskinesias, Movement Disorders, Central Nervous System Diseases","enrollment":30},{"nctId":"NCT03781167","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-29","conditions":"Parkinson's Disease (PD)","enrollment":244},{"nctId":"NCT06021756","phase":"PHASE1","title":"Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2019-07-28","conditions":"Levodopa-Induced Dyskinesia, Parkinson's Disease","enrollment":9},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT05094050","phase":"PHASE1","title":"Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-01-18","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00660673","phase":"PHASE3","title":"Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-11-13","conditions":"Advanced Parkinson's Disease","enrollment":262},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174},{"nctId":"NCT03065192","phase":"PHASE1","title":"Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-05-11","conditions":"Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease","enrollment":16},{"nctId":"NCT01736176","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2013-03","conditions":"Advanced Parkinson's Disease","enrollment":39},{"nctId":"NCT03419806","phase":"PHASE1","title":"Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2018-02-16","conditions":"Parkinson Disease","enrollment":25},{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":"Parkinson's Disease (PD)","enrollment":63},{"nctId":"NCT01973543","phase":"PHASE1","title":"Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2013-10","conditions":"Parkinson's Disease","enrollment":15},{"nctId":"NCT02782481","phase":"PHASE3","title":"A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations","status":"WITHDRAWN","sponsor":"NeuroDerm Ltd.","startDate":"2016-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02701803","phase":"","title":"Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy","status":"COMPLETED","sponsor":"Hospital District of Helsinki and Uusimaa","startDate":"2015-10","conditions":"Parkinson's Disease","enrollment":8},{"nctId":"NCT01283594","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off","status":"COMPLETED","sponsor":"Biotie Therapies Inc.","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT03793491","phase":"","title":"Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-12-18","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT03462043","phase":"PHASE3","title":"A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension","status":"WITHDRAWN","sponsor":"NeuroDerm Ltd.","startDate":"2018-04-10","conditions":"Parkinson","enrollment":""},{"nctId":"NCT00845000","phase":"PHASE1","title":"Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-21","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT01754129","phase":"","title":"Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Parkinson's Disease","enrollment":148},{"nctId":"NCT03602924","phase":"","title":"Long-term Safety and Effectiveness of Levodopa-carbidopa Intestinal Gel Infusion","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2008-12-01","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT01960842","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Advanced Parkinson's Disease","enrollment":31},{"nctId":"NCT00141518","phase":"PHASE4","title":"Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2006-03","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":77},{"nctId":"NCT02448914","phase":"PHASE1","title":"A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients","status":"COMPLETED","sponsor":"LobSor Pharmaceuticals AB","startDate":"2015-05","conditions":"Parkinson's Disease","enrollment":11},{"nctId":"NCT01479127","phase":"PHASE2","title":"Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Advanced Parkinson's Disease","enrollment":8},{"nctId":"NCT00505843","phase":"PHASE1","title":"A Study of MK0657 in Parkinson's Disease Patients (0657-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT00360568","phase":"PHASE3","title":"Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-06","conditions":"Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations","enrollment":62},{"nctId":"NCT00335153","phase":"PHASE3","title":"Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-01","conditions":"Advanced Parkinson's Disease","enrollment":354},{"nctId":"NCT00357994","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01","conditions":"Advanced Parkinson's Disease","enrollment":36},{"nctId":"NCT00660387","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Advanced Parkinson's Disease","enrollment":35},{"nctId":"NCT00914134","phase":"PHASE4","title":"Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT00906828","phase":"PHASE4","title":"Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2008-10","conditions":"Parkinson Disease","enrollment":10},{"nctId":"NCT00888186","phase":"PHASE4","title":"Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2008-02","conditions":"Parkinson Disease, Dyskinesias","enrollment":5},{"nctId":"NCT00001928","phase":"","title":"Intravenous Levodopa for the Diagnosis of Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1999-03","conditions":"Parkinson Disease","enrollment":25},{"nctId":"NCT00006077","phase":"PHASE2","title":"Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2000-08","conditions":"Parkinson's Disease","enrollment":50},{"nctId":"NCT00013624","phase":"PHASE2","title":"Riluzole to Treat Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2001-03","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT00009048","phase":"PHASE2","title":"EMD 128130 for the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2001-01","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT00040209","phase":"PHASE2","title":"JP-1730 to Treat Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-06","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT00006337","phase":"PHASE2","title":"KW-6002 to Treat Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2000-10","conditions":"Parkinson's Disease","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":180,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duodopa"],"phase":"marketed","status":"active","brandName":"Levodopa infusion","genericName":"Levodopa infusion","companyName":"University of Helsinki","companyId":"university-of-helsinki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease. Used for Advanced Parkinson's disease with motor fluctuations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}